In hypothesis testing, **Type I** and **Type II errors** are the two primary types of mistakes that can occur when making decisions about the null hypothesis $(\(H_0\))$ based on sample data. These errors represent the risks inherent in statistical testing, and understanding them is crucial for interpreting results and designing robust experiments. Below is a detailed explanation of Type I and Type II errors, including their definitions, probabilities, consequences, and strategies to manage them, along with examples and practical considerations.

---

### **1. Definitions**

#### **a. Type I Error (False Positive)**
- A **Type I error** occurs when the null hypothesis $(\(H_0\))$ is **rejected** when it is actually **true**.
- In other words, it’s concluding that there is an effect or difference when none exists in the population.
- **Probability**: Denoted by $\(\alpha\), the **significance level**, which is the threshold for rejecting \(H_0\) (e.g., \(\alpha = 0.05\)$ means a 5% chance of a Type I error).
- **Analogy**: Convicting an innocent person in a trial (saying they’re guilty when they’re not).
- **Example**: 
  - $\(H_0\)$: A drug has no effect on blood pressure.
  - Type I error: Concluding the drug lowers blood pressure $(rejecting \(H_0\))$ when it actually has no effect.

#### **b. Type II Error (False Negative)**
- A **Type II error** occurs when the null hypothesis $(\(H_0\))$ is **not rejected** when it is actually **false**.
- In other words, it’s failing to detect an effect or difference that exists in the population.
- **Probability**: Denoted by $\(\beta\)$, the probability of a Type II error. The **power** of a test is $\(1 - \beta\)$, the probability of correctly rejecting a false $\(H_0\)$.
- **Analogy**: Acquitting a guilty person in a trial (saying they’re not guilty when they are).
- **Example**:
  - \(H_0\): A drug has no effect on blood pressure.
  - Type II error: Concluding the drug has no effect (failing to reject $\(H_0\)$) when it actually lowers blood pressure.

---

### **2. Summary Table**

| Error Type | Definition | Probability | Consequence | Analogy |
|------------|------------|-------------|-------------|---------|
| **Type I** | Reject $\(H_0\)$ when $\(H_0\)$ is true | $\(\alpha\)$ (significance level) | False positive: Claiming an effect that doesn’t exist | Convicting an innocent person |
| **Type II** | Fail to reject $\(H_0\)$ when $\(H_0\)$ is false | $\(\beta\)$ | False negative: Missing a real effect | Acquitting a guilty person |

---

### **3. Mathematical Context**

#### **a. Type I Error $(\(\alpha\))$**
- The probability of a Type I error is set by the researcher as the significance level $(\(\alpha\))$ when designing the test.
- For a two-tailed test with $\(\alpha = 0.05\)$, the critical region (where $\(H_0\)$ is rejected) is split into two tails of the distribution (e.g., $\(z > 1.96\) or \(z < -1.96\)$ for a z-test).
- Example: If $\(\alpha = 0.05\)$, there’s a 5% chance of rejecting $\(H_0\)$ when it is true.

#### **b. Type II Error $(\(\beta\))$**
- The probability of a Type II error depends on:
  - **Effect size**: The magnitude of the true difference or effect (larger effects are easier to detect).
  - **Sample size $(\(n\))$**: Larger samples reduce $\(\beta\)$ by increasing precision.
  - **Significance level $(\(\alpha\))$**: A smaller $\(\alpha\)$ (stricter threshold) increases $\(\beta\).$
  - **Population variability**: Higher variability increases $\(\beta\)$.
- Calculating $\(\beta\)$ requires specifying the true parameter value under $\(H_1\)$ and involves the sampling distribution under the alternative hypothesis.

#### **c. Power $(\(1 - \beta\))$**
- **Power** is the probability of correctly rejecting a false $\(H_0\)$, calculated as $\(1 - \beta\).$
- Power depends on the same factors as $\(\beta\)$. A test with high power (e.g., $\(1 - \beta \geq 0.8\)$) is more likely to detect a true effect.

---

### **4. Practical Example**

**Scenario**: A pharmaceutical company tests a new drug to see if it reduces cholesterol levels compared to a placebo. The population mean cholesterol reduction for the placebo is 0 mg/dL, with a standard deviation of 10 mg/dL. A sample of 50 patients on the drug has a mean reduction of 3 mg/dL. Test at $\(\alpha = 0.05\)$ whether the drug reduces cholesterol.

- **Hypotheses**:
  - $\(H_0: \mu = 0\)$ (the drug has no effect on cholesterol).
  - $\(H_1: \mu > 0\)$ (the drug reduces cholesterol, right-tailed).

- **Test Statistic (z-test, known variance)**:
 <img width="462" height="83" alt="image" src="https://github.com/user-attachments/assets/352a7f76-bf39-4663-b28c-85844ed8050b" />


- **P-value**:
  - For a right-tailed test: $\(p = P(Z > 2.12) \approx 0.017\)$ (from z-table).

- **Decision**:
  - Since $\(p = 0.017 \leq \alpha = 0.05\)$, reject $\(H_0\).$

- **Type I Error**:
  - If $\(H_0\)$ is true $(\(\mu = 0\))$, there’s a 5% chance $(\(\alpha = 0.05\))$ of incorrectly rejecting $\(H_0\)$ and concluding the drug reduces cholesterol when it doesn’t.
  - Consequence: The company might market an ineffective drug, leading to wasted resources or false patient expectations.

- **Type II Error**:
  - If $\(H_0\)$ is false (e.g., true $\(\mu = 5\)$ mg/dL), a Type II error occurs if we fail to reject $\(H_0\)$, missing the drug’s true effect.
  - Calculating $\(\beta\)$ requires the true $\(\mu\)$. Suppose the true $\(\mu = 5\)$:
    - Under $\(H_1\)$, the test statistic’s distribution is centered at:
      <img width="593" height="139" alt="image" src="https://github.com/user-attachments/assets/98ef1d55-1b24-434e-b040-059664e6d419" />

    <img width="895" height="260" alt="image" src="https://github.com/user-attachments/assets/89940f81-5dc6-43d0-bda5-1aef782c4c2b" />

  - Consequence: Failing to detect the drug’s effect could delay or prevent its approval, missing potential benefits for patients.

---

### **5. Trade-Off Between Type I and Type II Errors**
- **Inverse Relationship**: Decreasing $\(\alpha\)$ (e.g., from 0.05 to 0.01) reduces the risk of a Type I error but increases the risk of a Type II error $(\(\beta\))$, lowering power.
- **Balancing Errors**:
  - In medical trials, a smaller $\(\alpha\)$ (e.g., 0.01) is often used to minimize Type I errors (avoiding false claims of drug efficacy).
  - In exploratory research, a larger $\(\alpha\)$ (e.g., 0.10) may be used to increase power and detect effects, accepting a higher Type I error risk.

---

### **6. Factors Affecting Errors**
- **Sample Size $(\(n\))$**:
  - Larger samples reduce $\(\beta\)$ (increase power) by improving precision, without affecting $\(\alpha\)$.
- **Effect Size**:
  - Larger differences between the true parameter and $\(H_0\) reduce \(\beta\).$
- **Significance Level $(\(\alpha\))$**:
  - Smaller $\(\alpha\) increases \(\beta\)$, reducing power.
- **Population Variability**:
  - Higher variability increases $\(\beta\)$, making it harder to detect effects.

---

### **7. Strategies to Minimize Errors**
- **Reduce Type I Error**:
  - Use a smaller $\(\alpha\)$ (e.g., 0.01 instead of 0.05).
  - Adjust for multiple testing (e.g., Bonferroni correction: divide \(\alpha\) by the number of tests).
- **Reduce Type II Error**:
  - Increase sample size to improve precision.
  - Increase $\(\alpha\)$ (e.g., from 0.01 to 0.05) to boost power, if appropriate.
  - Use more sensitive tests or reduce measurement variability.
- **Power Analysis**:
  - Conduct a power analysis before the study to determine the sample size needed to achieve a desired power (e.g., $\(1 - \beta = 0.8\)$) for a specific effect size and $\(\alpha\)$.

---

### **8. Practical Considerations**
- **Context Matters**:
  - In fields like medicine, Type I errors (false positives) are often more costly (e.g., approving an ineffective drug), so a smaller \$(\alpha\)$ is preferred.
  - In early-stage research, Type II errors (missing real effects) may be more costly, so higher power or a larger $\(\alpha\)$ may be acceptable.
- **Misinterpretations**:
  - Failing to reject $\(H_0\)$ does not prove $\(H_0\)$ is true; it indicates insufficient evidence against it (possible Type II error).
  - Rejecting $\(H_0\)$ does not prove $\(H_1\)$; it suggests evidence supporting $\(H_1\)$.
- **Reporting**:
  - Report both p-values and effect sizes to provide context for statistical significance and practical importance.

---

### **9. Applications**
- **Medical Research**: Avoiding Type I errors ensures only effective treatments are approved; minimizing Type II errors ensures effective treatments aren’t overlooked.
- **Business**: Type I errors might lead to adopting ineffective strategies; Type II errors might miss profitable opportunities.
- **Social Sciences**: Balancing errors ensures valid conclusions about population behaviors or relationships.

---

### **10. Python Implementation (Power Calculation)**
To estimate $\(\beta\)$ and power for the above example $(\(\mu = 5\), \(\alpha = 0.05\))$:

```python
from scipy import stats
import numpy as np

# Parameters
mu_0 = 0       # Null hypothesis mean
mu_true = 5    # True mean under H1
sigma = 10     # Population standard deviation
n = 50         # Sample size
alpha = 0.05   # Significance level

# Critical value for right-tailed test
z_critical = stats.norm.ppf(1 - alpha)  # ≈ 1.645

# Calculate beta (Type II error probability)
se = sigma / np.sqrt(n)  # Standard error
z_beta = (z_critical * se - (mu_true - mu_0)) / se
beta = stats.norm.cdf(z_beta)
power = 1 - beta

print(f"Beta (Type II error probability): {beta:.3f}")
print(f"Power (1 - Beta): {power:.3f}")
```

**Output**:
```
Beta (Type II error probability): 0.027
Power (1 - Beta): 0.973
```

---

In summary, **Type I errors** (false positives, probability $\(\alpha\))$ occur when rejecting a true $\(H_0\)$, while **Type II errors** (false negatives, probability $\(\beta\)$) occur when failing to reject a false $\(H_0\)$. Balancing these errors involves trade-offs influenced by sample size, effect size, and $\(\alpha\)$. If you have a specific scenario, dataset, or further questions (e.g., calculating power for a different test), let me know, and I can provide a tailored example or analysis!
